Co-amilozide
Combination medication
- C03EA01 (WHO)
- UK: POM (Prescription only)
- 57017-78-4
- 107748
- 96911 Y
- DTXSID90218652
Co-amilozide (BAN) is a non-proprietary combination of amiloride and hydrochlorothiazide. Co-amilozide is used in the treatment of hypertension and congestive heart failure with the tendency of the thiazide to cause low potassium levels (hypokalaemia) offset by the potassium-sparing effects of amiloride.
Formulation
Two strengths of co-amilozide are currently available in the UK:[1]
- 2.5 mg amiloride and 25 mg hydrochlorothiazide, BAN of Co-amilozide 2.5/25 (brand name Moduret 25)
- 5 mg amiloride and 50 mg hydrochlorothiazide, BAN of Co-amilozide 5/50 (brand name Moduretic)
In North America:
- Moduretic (U.S., Canada)
- Moduretic 5-50 (U.S., Canada)
- Novamilor (Canada)
Side effects
The most common side effect is headache (about 8% of people taking it) and nausea, loss of appetite, weakness, rash and dizziness (each about 3%).[2]
Common side effects (1/10 - 1/100) include:[2]
- General: weakness, fatigue, loss of appetite, headache, dizziness.
- Circulatory system: arrhythmia.
- Gastrointestinal: nausea, diarrhea, abdominal pain.
- Skin: exanthema, itching.
- Respiratory system: shortness of breath, cough.
- Metabolic: elevated blood sugar in diabetic patients, elevated uric acid levels in the blood.
- Musculoskeletal: pain in the limbs.
References
- ^ British National Formulary 54 September 2007
- ^ a b the Swedish official drug catalog > Normorix Retrieved on Mars 30, 2010
- v
- t
- e
(antagonize α-adrenergic
vasoconstriction)
Central |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Peripheral |
|
Serotonin receptor antagonists | |
---|---|
Endothelin receptor antagonists (for PHTooltip Pulmonary hypertension) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e